-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Improving Symptom Control for Children with Hematological Malignancies

Program: Education Program
Hematology Disease Topics & Pathways:
Adverse Events, Pediatric, Study Population, Clinically relevant, Quality Improvement
Monday, December 7, 2020: 6:55 AM-7:00 AM

Description:
Dr. Lillian Sung will describe the importance of symptom control in children with cancer, and approaches to identify symptoms amenable to clinical implementation. Topics will include child self-report, parent proxy-report and a novel collaborative approach involving child and parent dyads. Recent research will be reviewed along with approaches toward clinical implementation that allow program evaluation.

Dr. Tamara P. Miller will discuss the current method of capturing treatment toxicities on pediatric hematology clinical trials, under-reporting of toxicities using the existing system, and the specific challenges related to pediatric trials. Potential solutions to improve adverse event ascertainment, including using electronic health record data, will be described.

Dr Robert Phillips will discuss approaches to control toxicity and aversive symptoms, from preventative strategies to therapeutic approaches. The importance of patient and parent involvement and the trade-offs we must make in such strategies will be considered, contextualizing recent research and outlining how future research could be improved.​"

Chair:
Lillian Sung, MD, PhD, Division of Hematology/Oncology, Department of Pediatrics, Hospital for Sick Children
Disclosures:
No relevant conflicts of interest to declare.
Dr. Lillian Sung will describe the importance of symptom control in children with cancer, and approaches to identify symptoms amenable to clinical implementation. Topics will include child self-report, parent proxy-report and a novel collaborative approach involving child and parent dyads. Recent research will be reviewed along with approaches toward clinical implementation that allow program evaluation.

Dr. Tamara P. Miller will discuss the current method of capturing treatment toxicities on pediatric hematology clinical trials, under-reporting of toxicities using the existing system, and the specific challenges related to pediatric trials. Potential solutions to improve adverse event ascertainment, including using electronic health record data, will be described.

Dr Robert Phillips will discuss approaches to control toxicity and aversive symptoms, from preventative strategies to therapeutic approaches. The importance of patient and parent involvement and the trade-offs we must make in such strategies will be considered, contextualizing recent research and outlining how future research could be improved.​"

Lillian Sung, MD, PhD

Division of Hematology/Oncology, Department of Pediatrics, Hospital for Sick Children, Toronto, Canada

Tamara P. Miller, MD, MSc

Aflac Cancer and Blood Disorders Center, Emory University School of Medicine/Children's Healthcare of Atlanta, Atlanta, GA; Emory, Decatur, GA

Robert Phillips, MD

Leeds Children's Hospital, Leeds, United Kingdom

See more of: Education Program